Predictive biomarker and clinicopathological characteristics analysis for recurrence of early gastric cancer

• Published in: The Chinese-German journal of clinical oncology Vol. 10; no. 7; pp. 394 - 398
• Main Authors: Yang, Jiyuan, Cai, Zhiqiang, Du, Wei, Li, Junchuan, Chen, Tingxuan, Xu, Yunhua
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.07.2011
• Subjects: Cancer Research; Medicine; Medicine & Public Health; Oncology; Surgical Oncology; 临床病理; 复发率; 早期; 生物标志物; 病理特征; 胃癌; 计算机断层扫描; 预测性; recurrence; gene, cerbB2; immunohistochemistry (IHC); hybridization (FISH); early gastric cancer (EGC); fluorescence
• ISSN: 1610-1979; 1613-9089
• DOI: 10.1007/s10330-011-0800-0

Objective： The aim of this study was to identify the correlation between the clinicopathological characteristics and recurrence in early gastric cancer （EGC）, what’s more, we attempt to look for a predictive biomarker to predict and treat for re-currence of EGC. Methods： This study retrospectively analyzed 178 early gastric cancer patients who had the complete post-operative and follow-up medical records in the First Affiliated Hospital of Yangtze University （China） between January 1995 to December 2005. All of them were followed-up to December 2009 regularly. Computer tomography （CT）, endoscopy, and single photon emission computed tomography （SPET-CT） were used to diagnose for recurrence of EGC. Immunohistochem-istry （IHC） and fluorescence in situ hybridization （FISH） were used for the detection of cerbB2. Chi-square test was applied to this study for statistics analysis. Results： Fourteen patients had recurrence. Eighteen patients were cerbB2-positive, including twelve recurrence patients and six norecurrence patients. Sex, tumor depth, and lymph node metastasis were related to the recurrence of EGC. Also, cerbB2-positive patients had the higher recurrence rate compared to the cerbB2-negative patients. Conclusion： Recurrence of EGC after curative resection can be predicted by using some clinicopathological characteristics. CerbB2 can be used as a predictive biomarker for recurrence of EGC.